Sorbinil

Sorbinil
Structural formula of sorbinil
Ball-and-stick model of the sorbinil molecule
Names
IUPAC name
(4S)-6-Fluoro-2,3-dihydro-2’H,5’H-spiro[chromene-4,4’-imidazolidine]-2’,5’-dione
Other names
(S)-6-Fluorospiro(chroman-4,4'-imidazolidine)-2',5'-dione; CP 45634
Identifiers
68367-52-2
ChEMBL ChEMBL7681
ChemSpider 298991
7415
Jmol interactive 3D Image
PubChem 337359
UNII G4186B906P YesY
Properties[1]
C11H9FN2O3
Molar mass 236.20 g·mol−1
Appearance White to off-white powder
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Sorbinil is an aldose reductase inhibitor being investigated for treatment of diabetic complications including neuropathy and retinopathy.[2] Aldose reductase is an enzyme present in lens and brain that gets rid of excess glucose by converting it to sorbitol. Sorbitol accumulation can lead to the development of cataracts in the lens and neuropathy in peripheral nerves. Sorbinil has been shown to inhibit aldose reductase in human brain[3] and placenta[4] and calf[5] and rat lens.[4] Sorbinil reduced sorbitol accummulation in rat lens and sciatic nerve of diabetic rats orally administered 0.25mg/kg sorbinil.[4]

References

  1. Sorbinil at Sigma-Aldrich
  2. MacCari, R; Del Corso, A; Giglio, M; Moschini, R; Mura, U; Ottanà, R (2011). "In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors". Bioorganic & Medicinal Chemistry Letters 21 (1): 200–3. doi:10.1016/j.bmcl.2010.11.041. PMID 21129963.
  3. O'Brien MM; et al. (1982). "Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil". J Neurochem 39: 810–4. doi:10.1111/j.1471-4159.1982.tb07964.x. PMID 6808090.
  4. 1 2 3 Kinoshita JH; et al. (1979). "Aldose reductase in diabetic complications of the eye". Metabolism 28 (suppl 1): 462–9. doi:10.1016/0026-0495(79)90057-x. PMID 45423.
  5. Peterson MJ; et al. (1979). "CP45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.". Metabolism 39 (Suppl 1): 456–61. doi:10.1016/0026-0495(79)90056-8. PMID 122297.
This article is issued from Wikipedia - version of the Wednesday, January 20, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.